



## **Newsmakers in the Biotech Industry Investment Conference to Webcast Alkermes' Corporate Presentation**

August 26, 2004

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 26, 2004--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by BioCentury and Thomson Financial on Thursday, September 9, 2004 at 12:00pm EDT from the Millennium Broadway Hotel in New York. The presentation may be accessed under the investor relations tab at [www.alkermes.com](http://www.alkermes.com) and will be archived for 14 days.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, Risperdal(R) Consta(TM) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag, a division of Johnson & Johnson. The Company's lead proprietary product candidate, Vivitrex(R) ((naltrexone) long-acting injection), is a once-a-month injection for the treatment of alcohol dependence. Alkermes has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technology and expertise. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Rebecca Peterson  
Director, Corporate Communications  
Alkermes, Inc.  
(617) 583-6378

SOURCE: Alkermes, Inc.